MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Tag: axicabtagene ciloleucel

axicabtagene ciloleucel

Latest news

Tag

Clinical Updates

Clinical Evolution of Axicabtagene Ciloleucel: From Salvage Therapy to Second-Line Standard of Care

This review synthesizes clinical trial evidence for Axicabtagene Ciloleucel, tracing its development from refractory B-cell lymphoma to its current role as a second-line standard and its expansion into indolent and mantle cell lymphomas.

Jan 13, 2026
Hematology-Oncology

Five-Year ZUMA-5 Follow-Up: Durable Remissions and Potential for Cure with Axicabtagene Ciloleucel in Relapsed/Refractory Follicular Lymphoma

Five-year outcomes from ZUMA-5 show axi-cel produces high response rates in relapsed/refractory indolent NHL, with 75% CR, median PFS ~62 months, durable remissions linked to early CAR T expansion and naïve T-cell product phenotype, and an

Dec 9, 2025

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story